Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Governance Other
confidence 75%
filed 2026-07-31
Item 8.01
This disclosure concerns a stockholder nomination request for a Board seat from Andrew Schornack and other Reporting Persons (identified in a Schedule 13D/A filed July 29, 2026). The Company has indicated the request will be considered by the Governance and Nomination Committee. While no appointment has occurred and the outcome is uncertain, the filing of a Schedule 13D/A coupled with a formal Board nomination request signals potential activist involvement and governance contestation, which is material to investors assessing control and board composition. This is a governance event that does not fit the specific categories of exec_appointment (no appointment yet) or exec_departure, making governance_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-31
Item 8.01
Interactive Brokers took down 2,499,567 shares of common stock from its shelf Registration Statement on Form S-3 via a Prospectus Supplement under Rule 424(b)(5). This is a registered public offering of equity securities that will dilute existing shareholders. The specific share count and reference to the shelf takedown mechanism indicate a material capital-raising transaction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-31
Item 8.01
Interactive Brokers filed a Prospectus Supplement under Rule 424(b)(5) to register up to 920,000 shares of common stock from its shelf Registration Statement on Form S-3. This is a registered offering of equity securities that will dilute existing shareholders. The filing of a prospectus supplement with a specific share count and legal opinion supporting validity indicates a material equity issuance event.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-31
Item 2.02
First Guaranty Bancshares released its Second Quarter 2026 Report to shareholders on July 31, 2026, disclosing quarterly financial results including net income of $3.4 million, earnings per common share of $0.17, and consolidated balance sheet and income statement data. The filing explicitly states "The Press Release is enclosed as Exhibit 99.1 to this report" and Item 2.02 is the standard Item for disclosure of quarterly financial results. This is a routine but material earnings release typical of quarterly 8-K filings.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-31
Item 1.01
Planet 13 entered into a definitive merger agreement with Vireo Growth Inc. on July 26, 2026, whereby Vireo will acquire all outstanding equity interests of Planet 13 through a merger with a wholly owned subsidiary. The merger consideration is 0.015383618 Parent Shares per Company Common Stock share. This is a material acquisition/change of control transaction requiring stockholder approval and satisfying the definition of ma_activity under Item 1.01.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-31
Item 2.02
Standex disclosed fourth quarter and fiscal year 2026 financial results, reporting Q4 FY26 sales of $228.3 million (7.7% organic growth) and record adjusted EPS of $2.45 (up 7.4% YOY), with full-year FY26 adjusted EPS of $8.74 (up 9.6% YOY), along with segment performance and forward guidance for FY27.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-31
Item 5.02
Alan J. Glass, Vice President, Chief Legal Officer & Secretary and a named executive officer, notified the Company on July 30, 2026 of his intent to retire, with transition arrangements through January 4, 2027.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-07-31
EX-99.1
This is an announcement of the timing and logistics for the release of second quarter 2026 financial results, scheduled for August 13, 2026. Although the actual results are not disclosed in this exhibit, the announcement itself constitutes an earnings release notification — a standard disclosure of when quarterly financial results will be made public, including conference call details and share count information. The inclusion of fully diluted share counts (160,673,515 and 159,641,222) and average pricing data further supports classification as an earnings-related disclosure material to investors assessing the company's capital structure and performance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-31
Item 7.01
Moleculin disclosed updated preliminary blinded interim results from its pivotal Phase 2/3 MIRACLE trial of Annamycin for R/R AML, reporting a 37% composite complete remission rate in 62 evaluable subjects, with notably consistent efficacy (37% CRc) in the 48% subgroup that had failed prior venetoclax therapy. This is a material clinical trial milestone disclosure that does not fit the earnings_release category (which typically reports financial results) but represents a significant operational/clinical development event that would affect investor assessment of the company's lead program advancement and regulatory pathway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-07-31
Item 7.01
The Company posted a presentation of Q2 2026 financial information for its subsidiary Patriot Bank on its Investor Relations website and furnished it as an exhibit to the 8-K. This constitutes disclosure of quarterly financial results, which is a material event affecting investor assessment of the registrant's financial performance and condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-31
Item 2.02
Stablecoin Development Corp disclosed Q2 2026 financial results for the quarter ended June 30, 2026, reporting staking revenue of $2.2 million, an operating loss of $53.8 million, and a net loss of $41.1 million per share, along with updated SKY holdings and accumulated staking rewards.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-31
Item 3.02
Catheter Precision closed a Series C-4 Convertible Preferred Stock offering on July 30, 2026, issuing 2,821 shares for $2.821 million in gross proceeds under Section 4(a)(2) and Regulation D Rule 506(b) exemptions. Conversion of the Series C-4 Preferred Stock into Common Stock will result in dilution of existing Common Stock holders, with the preferred shares carrying senior ranking with respect to dividends and liquidation preferences.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-31
Item 2.02
Proto Labs issued a press release on July 31, 2026 announcing second quarter 2026 financial results, including record quarterly revenue of $149.3 million (10.6% YoY growth), GAAP EPS of $0.37, and raised full-year 2026 revenue guidance from 6-8% to 8-10%. The filing discloses quarterly earnings with detailed financial statements and forward guidance, which is the classic structure of an earnings release under Item 2.02.
View raw filing on EDGAR →
6-K
Earnings release
confidence 97%
filed 2026-07-31
EX-99.1
VEON disclosed financial results for the second quarter and first half of 2026, reporting total revenue of USD 1,271 million (+17.0% YoY) and EBITDA of USD 552 million (+6.2% YoY), with diluted EPS of USD 1.69. The company raised its full-year 2026 guidance, projecting revenue growth of 15%–18% YoY and EBITDA growth of 9%–12% YoY.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 88%
filed 2026-07-31
Item 1.01
BTCS Labs Inc. issued an unsecured promissory note for $25,000 principal to its CEO Charles Allen on July 29, 2026, with a 6% standard interest rate (15% upon default) and a maturity date of December 31, 2030 or upon board composition change. This represents a material creation of a direct financial obligation that affects the company's capital structure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-31
Item 3.01
Nasdaq notified UPEXI on July 30, 2026, that the Company failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days, triggering a delisting notice under Nasdaq Listing Rule 5550(a)(2). Although the Company has been granted a 180-calendar-day compliance period until January 26, 2027, the notification letter itself constitutes a material delisting risk disclosure under Item 3.01, as it signals potential loss of listing if compliance is not regained.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-31
Item 1.01
The filing discloses entry into an Amendment No. 1 to a Letter of Intent for the acquisition of all outstanding equity interests of Advertise Purple, Inc. by ONAR Holding Corporation. The Company has committed a $1,000,000 down payment toward the purchase price, with a proposed securities purchase agreement substantially negotiated and attached. This constitutes a material acquisition activity under Item 1.01, with a defined transaction structure, timeline (Outside Date of August 27, 2026), and binding financial commitment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-31
Item 3.02
The Company exchanged 2,074 shares of Series B Preferred Stock (aggregate stated value $2,074,000) for 674,923 shares of common stock pursuant to unregistered exchange agreements with Streeterville Capital. This is a dilutive issuance of common stock conducted under Section 3(a)(9) exemption, representing a substantial increase in common share count that would materially affect existing shareholders' ownership percentages and voting power.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-31
Item 2.02
LyondellBasell announced second quarter 2026 earnings results on July 31, 2026, disclosing net income of $0.6 billion ($1.71 per diluted share) and EBITDA of $1.3 billion ($2.1 billion excluding identified items). The earnings release, furnished as Exhibit 99.1, is the core disclosure under Item 2.02 and includes quarterly financial results, segment performance, cash flow, and forward guidance—all hallmarks of a standard earnings release material to investors.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-31
EX-99.1
The exhibit announces that Diginex has regained compliance with Nasdaq's Minimum Bid Price Requirement (Rule 5550(a)(2)) after receiving a non-compliance notice on March 23, 2026. The company had been below the $1.00 minimum bid price threshold and faced a 180-day cure period ending September 21, 2026. This disclosure directly addresses delisting risk — the core material event is the company's prior non-compliance and the regulatory jeopardy it created, now resolved. The announcement of regained compliance is material because it resolves an existential threat to the company's continued listing on Nasdaq.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-31
EX-99.1
This is an underwriting agreement for a public offering of 1,491,305 common shares at US$3.76 per share (with a 6% underwriting discount), plus an over-allotment option for up to 223,695 additional shares. The agreement explicitly references a Form F-10 registration statement and prospectus supplement filed with the SEC, confirming this is a registered public offering. This constitutes a dilutive issuance of equity securities that would materially affect a reasonable investor's assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-31
The filing discloses completion of a material acquisition on July 31, 2026, whereby Dragonfly Energy acquired substantially all operating assets of the Dakota Lithium brand for $4.0 million ($1 million cash plus 1.5 million shares valued at $3 million). Item 1.01 explicitly covers "Entry into a Material Definitive Agreement" for the asset purchase, and the press release emphasizes this as a "strategic acquisition" expected to contribute meaningful revenue and be accretive to Adjusted EBITDA by Q4 2026. The transaction also triggered concurrent debt amendments (Item 2.03) and an unregistered equity issuance (Item 3.02), all hallmarks of material M&A activity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-31
EX-99.1
EUDA Health announced a non-binding Memorandum of Understanding (MOU) signed July 15, 2026, with GO POSB and SIIT to collaborate on developing and commercializing integrated iPSC cell therapy products for oncology and wellness applications. The announcement details EUDA's role in funding, facilitating commercialization, and supporting global market access for next-generation cell therapies. This is a material strategic partnership and operational initiative that would affect a reasonable investor's assessment of the company's growth strategy and future product pipeline, though the MOU is non-binding and subject to definitive agreements and regulatory approvals.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-31
Beyond Air entered into a securities purchase agreement on July 29, 2026, to issue 167,011 shares of common stock, 1,638,835 pre-funded warrants, and 3,611,692 common stock purchase warrants (Series A and B combined) in a private placement expected to raise approximately $10.2 million in gross proceeds upfront, with potential for up to $30.1 million if all warrants are exercised. This is a classic dilutive private placement with warrants, materially affecting shareholder equity and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-31
Co-Diagnostics entered into an inducement agreement on July 30, 2026, whereby warrant holders exercised existing warrants for approximately $2.67 million in gross proceeds, and the Company issued new warrants to purchase 3,404,724 additional shares at $1.56 per share. This is a dilutive equity issuance structured as a warrant exchange that increases outstanding shares from 5,277,846 to 6,980,208 (32% dilution) and requires future stockholder approval. The transaction is material to investors as it substantially dilutes existing shareholders and raises capital through equity rather than debt.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-31
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of the 2026 Annual Meeting of stockholders held on July 27, 2026. The filing presents voting results for six proposals: election of five directors (all passed with >92% support), approval of increased authorized shares (96.59% for), amendment to the 2020 Equity Incentive Plan (80.82% for), advisory say-on-pay vote (83.55% for), ratification of auditors (97.68% for), and other business (84.28% for). The detailed vote tallies and percentages are the core disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-31
The filing discloses that Nasdaq imposed a trading halt under Code T12 on June 12, 2026, and that the halt is now being lifted on July 31, 2026. Code T12 halts are typically issued for non-compliance with continued listing standards or disclosure requirements. While the company states it is "not aware of any material, undisclosed corporate developments," the fact that a trading halt was imposed and is only now being lifted signals a delisting risk event that would materially affect investor assessment of the registrant's listing status.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-31
Item 5.02
The filing discloses the appointment of three new directors (Carlos Septién, Michelle Cervantes Vivanco, and Ernesto Gómez Berjón) and their simultaneous appointment as Chief Operating Officer, Chief Financial Officer, and Chief Growth Officer, respectively, effective July 29, 2026. While the filing also includes governance amendments and a reverse stock split, the principal disclosed action centers on these executive and board appointments, which are material to investors assessing the registrant's leadership and control structure, particularly in the context of Trafalgar Asset Management's acquisition of control.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-31
Galmed received notice from Nasdaq on July 30, 2026, that it has failed to maintain the minimum $1 bid price per share requirement and has been granted an additional 180-day compliance period (until January 25, 2027) to cure the deficiency. This is a classic delisting-risk disclosure under Item 3.01 — the company faces potential delisting if it cannot regain compliance within the extended cure period.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 85%
filed 2026-07-31
The 6-K discloses results of an Extraordinary Shareholders' Meeting held July 29, 2026, where shareholders approved three material proposals: (1) delegation to the Board to increase share capital by up to €300 million and issue up to 120 million new shares and convertible bonds; (2) authorization for a reverse stock split at a 1-for-10 to 1-for-20 ratio to maintain Nasdaq compliance. While a corporate name-change proposal was deferred, the approved resolutions grant significant capital-raising and restructuring authority that would materially affect investors' assessment of dilution risk and the company's financial flexibility.
View raw filing on EDGAR →
6-K
Bankruptcy Filing
confidence 95%
filed 2026-07-31
On July 31, 2026, UMB Bank (acting through OIC Structured Equity Fund I GPFA Range, LLC) filed a petition with the High Court of Ireland seeking winding up and liquidation of Carbon Revolution Public Limited Company under section 569(1)(d) of the Companies Act 2014 on grounds of insolvency. The High Court subsequently appointed joint liquidators on a provisional basis, with a hearing scheduled for October 19, 2026. This constitutes a bankruptcy/insolvency filing under Irish law—a terminal event materially threatening the registrant's continued existence.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-31
The filing discloses entry into a material consulting agreement (Item 1.01) with Aibot US Operation Inc for ongoing operational support across finance, capital markets, and HR/legal functions at $50,000 monthly. While this is a material definitive agreement, it is a consulting/service arrangement rather than a traditional M&A transaction, debt issuance, or other specifically-named event type. The related-party nature (CEO Jerry Wang has minority ownership in Aibot) and board approval reinforce materiality, but the core event is an operational service engagement that does not fit the narrower financial or governance categories.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-31
The filing discloses the appointment of two new directors—Pua Chee Aun and Lee Seongil—to the Board on July 28, 2026, with both appointed to the Audit and Compensation Committees. While the filing also mentions the resignation of Li Wei and Michael Coyne, the substantive focus and forward-looking action is the appointment of the two new directors with specified class terms and committee roles. For a SPAC or acquisition company, board composition changes are material to investors assessing governance and strategic direction.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-31
The filing discloses entry into private placement agreements for the unregistered sale of 677,084 shares of common stock at $4.80 per share for approximately $3.25 million in aggregate gross proceeds. Items 1.01 and 3.02 explicitly describe the issuance as unregistered equity securities expected to be issued under Regulation S, which is a classic dilutive issuance. The involvement of related parties (the CEO's brothers) and the use of proceeds for general corporate purposes and potential strategic investments further support materiality to investors.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-31
The filing discloses two executive departures: Todd Pepmeier's resignation as Chief Financial Officer effective August 10, 2026, and Laurie Tucker's resignation as a director on July 29, 2026. The principal disclosed action is persons leaving their roles. While both departures are disclosed, the CFO departure is the more material event given the criticality of the financial officer role. The filing explicitly states Ms. Tucker's departure was not due to disagreement, suggesting routine director transition.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-31
EX-99.1
Core AI received a Nasdaq notification on July 31, 2026 that it failed to maintain the minimum $1.00 bid price requirement for 30 consecutive trading days (June 17–July 30, 2026). The company has 180 days to regain compliance or faces delisting; if it fails to cure and does not qualify for a second compliance period, Nasdaq will issue a delisting determination. This is a material disclosure of delisting risk under the taxonomy.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-31
The filing discloses an Amendment No. 1 and Forbearance/Extension Agreement to an Asset Purchase Agreement dated July 23, 2026, whereby Cycurion agreed to extend the closing date of its acquisition of Kustom Entertainment's video-solutions division to on or about September 15, 2026. The Company paid $250,000 and agreed to issue Series H Preferred Stock valued at $600,000 as consideration for the extension. This is a material amendment to a previously disclosed material acquisition transaction (Item 1.01).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-31
Mira Pharmaceuticals received a notice from Nasdaq on July 27, 2026, that it failed to maintain the minimum bid price of $1 per share under Nasdaq Listing Rule 5550(a)(2). The company has been given 180 calendar days until January 25, 2027, to regain compliance, with the explicit warning that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-31
The filing discloses a 1-for-16 reverse stock split effected on July 30, 2026, explicitly stated as "a proactive measure intended to increase the per-share trading price, support the continued listing of its Common Stock on the NYSE American and reduce the risk that its Common Stock could become subject to delisting for failure to satisfy applicable continued listing standards." This is a material governance action directly addressing delisting risk under continued listing standards.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-31
Clean Energy Technologies entered into a securities purchase agreement with 1800 Diagonal Lending LLC to issue a convertible promissory note with principal of $147,840 for net funding of $125,000. The note is convertible into common stock at 85% of the lowest closing bid price, with conversion restrictions tied to beneficial ownership thresholds and Nasdaq Rule 5635(d) shareholder approval requirements. Item 3.02 explicitly discloses this as an unregistered sale of equity securities under Section 4(a)(2), and the convertible feature creates dilutive equity exposure typical of PIPE-like financing arrangements at small-cap issuers.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-31
bioAffinity Technologies received written notice from Nasdaq on July 30, 2026 that it failed to maintain the minimum bid price requirement of $1.00 per share for 30 consecutive business days and is not in compliance with Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-day compliance period due to a prior reverse stock split, creating immediate delisting risk. The company intends to appeal but faces substantial uncertainty about maintaining its listing on the Nasdaq Capital Market.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-31
EX-99.1
Uni-Fuels received a Nasdaq notification letter dated July 27, 2026, stating the company is not in compliance with the minimum closing bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days until January 25, 2027 to regain compliance, with a potential additional 180-day cure period if certain conditions are met. Failure to comply could result in delisting. This is a material disclosure of delisting risk that would significantly affect a reasonable investor's assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-31
The filing discloses unregistered sales of equity securities under Item 3.02, including issuance of pre-funded warrants to purchase 12,131,770 shares (representing a significant dilution) and 123,537 shares of common stock to service providers. The pre-funded warrants have an exercise price of $0.0001 per share and are contingent on stockholder approval for issuance in excess of 19.99% of outstanding common stock, indicating substantial dilutive potential. This is a classic private placement structure typical of small-cap equity raises.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-31
The filing discloses a business combination agreement entered into on March 6, 2026, between Calisa Acquisition Corp and Goodvision AI Inc., with Goodvision surviving as a direct, wholly owned subsidiary of the Company post-merger. The Item 7.01 disclosure furnishes an investor presentation regarding the proposed transaction. This is a material acquisition/merger activity that would substantially affect the registrant's structure and is central to the filing's purpose.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-07-31
EX-99.1
This is a quarterly earnings press release for Q2 2026 disclosing financial results including revenue of $2,152 million, adjusted EBITDA of $1,064 million, earnings of $512 million, and earnings per share of $0.83 basic / $0.82 diluted. The document explicitly states "Pembina Pipeline Reports Results for the Second Quarter of 2026" and provides comprehensive financial and operational overview tables comparing 2026 to 2025 results, along with divisional performance and 2026 guidance. This is a material event affecting investor assessment of the registrant's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-31
Item 2.02
AbbVie issued a press release on July 31, 2026 announcing second-quarter 2026 financial results, including net revenues of $16.990 billion (up 10.2% reported, 9.5% operational), diluted EPS of $2.03 GAAP and adjusted diluted EPS of $3.65 (up 22.9%), along with detailed portfolio performance metrics and updated full-year 2026 guidance. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-31
Item 2.02
Eaton Corporation plc issued a press release on July 31, 2026, announcing its financial results for the quarter ended June 30, 2026, disclosing record second quarter sales of $8.5 billion (up 21%), adjusted earnings per share of $3.15 (a second quarter record), and raising full-year organic growth guidance to 11-13%. This is a standard quarterly earnings release with comprehensive financial statements and forward guidance, clearly falling under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-07-31
Item 8.01
News Corporation disclosed daily buy-back notifications under its $1 billion repurchase program authorized July 15, 2025, with approximately $396.6 million deployed to date across Class A and Class B common stock. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category as they represent a return of capital. The filing shows active execution with specific transaction details (10.1M+ shares bought back on July 30, 2026 at prices ranging $22.20–$29.06), making this material to investors assessing capital allocation and shareholder returns.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-07-31
Item 2.02
Gaming and Leisure Properties issued a press release on July 30, 2026 announcing financial results for the three and six months ended June 30, 2026, with detailed financial highlights showing record revenue of $430.5 million (up 9.0%), AFFO of $304.0 million (up 10.1%), and Adjusted EBITDA of $405.5 million (up 12.2%), along with updated 2026 full-year AFFO guidance and a dividend increase. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-31
Item 2.03
Criteo entered into a material amendment to its Multicurrency Revolving Facility Agreement on July 29, 2026, modifying key terms including the borrower structure in connection with the company's planned redomiciliation from France to Luxembourg and potentially to the United States. The amendment addresses borrower resignation, potential subsequent accession, jurisdictional changes, and extension timelines—all material modifications to the credit agreement framework affecting the company's capital structure and financial flexibility.
View raw filing on EDGAR →